Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
pepeliaev.pro is the personal biotechnology consulting website of Dr. Stanislav Pepeliaev. It is positioned as an independent advisory service rather than a SaaS or enterprise software product. His background centers on biotechnology, biochemistry, process development, team management, technology transfer, scale-up manufacturing, strain engineering, cell line development, and upstream/downstream processing. The site states that he is based in the Greater Oxford area in the UK, has worked in the field since 2003, and lists experience with the University of Oxford, Ipsen, Contipro, and others.
Based on the website content, the core services fall into four areas: technology transfer, technical due diligence, bridging R&D and manufacturing, and biologics process development. The main value proposition is helping organizations turn laboratory discoveries into scalable, compliant, manufacturable processes, covering early-stage development, industrial manufacturing, GMP transfer, process optimization, and risk assessment. Publicly listed project areas include virus-like particles, recombinant proteins, polysaccharides, and DNA production, with an emphasis on automation, high-throughput methods, and process scale-up.
The website does not disclose packages, hourly rates, project-based pricing, payment methods, trials, or service-level agreements. It is therefore best understood as a customized professional consulting model rather than a standard subscription SaaS offering. Buyers would still need to contact the consultant directly to confirm scope, deliverables, timeline, confidentiality terms, and fee structure.
The main strength is a solid professional background: PhD-level expertise, long-term experience across industry and academic translation, management of multidisciplinary teams, plus listed patents and publications as evidence of capability. For biotechnology organizations that need process development, technology transfer, or investment due diligence, the fit is likely strong. The limitations are also clear: it does not provide the kinds of information typically associated with enterprise software, such as cloud deployment, access control, third-party integrations, APIs, dashboards, or automation platform features. The site also lacks detailed customer case studies, compliance certifications, support workflows, and other commercialization details.
It is best suited to biopharmaceutical companies, startups, research institutions, and investors that need external expertise during R&D scale-up, GMP transfer, or technical risk assessment. It is not suitable as a SaaS tool selection candidate. Access from mainland China is not described in the available text and should be considered unknown.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on pepeliaev.pro official site.
pepeliaev.pro is an Unknown Health provider. TG4G tracks its product information, an overall rating of 4.0/10, and a China-accessibility score of Workable. Click "Visit Official Site" to reach pepeliaev.pro directly.